▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4097 by analyst upside · 2026-09-29
BRKR
Bruker Corporation
Healthcare · Market Cap $10B · P/E 0x
ANALYST PRICE TARGET
-5.2%
implied upside to consensus target
Current Price $63.28
Consensus Target $60.0
Bull Target $70.0
Bear Target $50.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
5
Sell
0
52-Week Low $30.69
52-Week High $65.3
YTD Return +32.0%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) N/A
Forward P/E 26.5x
EPS (TTM) $-0.75
PEG Ratio 1.52
Dividend Yield 0.31%
Revenue (TTM) $3.5B
Profit Margin -2.0%
52-WEEK RANGE
52-Week Low $30.69
52-Week High $65.3
Current Price $63.28
Bear Target $50.0
Bull Target $70.0
● Now $63.28 ● Target $60.0
TRADING DATA
Avg Volume 2.2M
YTD Return +32.0%
Analyst Count 13
Consensus Buy
Upside to Target -5.2%
Last Updated 2026-09-29

ANALYST SUMMARY

Bruker Corporation (BRKR) is currently trading at $63.28 with a Wall Street consensus price target of $60.0, which is 5.2% below the current price over the next 12 months. 13 analysts currently cover BRKR, with a consensus rating of Buy - 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $70.0, while the most cautious has a target of $50.0.

BRKR operates in the Healthcare sector with a market capitalisation of $10B. The stock is up 32.0% year-to-date and is currently trading near the upper end of its 52-week range of $30.69 – $65.3.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BRKR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Neutral → Neutral 2026-09-09 33% win rate (6 calls)
Citigroup - Reiterated
Neutral → Neutral 2026-08-05 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-07-08 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-07-07 29% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-06-29 62% win rate (8 calls)
Barclays - Reiterated
Overweight → Overweight 2026-06-24 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-06-08 43% win rate (7 calls)
UBS - Reiterated
Neutral → Neutral 2026-05-07 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
20/30
Consensus clarity
24/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →